Alnylam Pharmaceuticals
NEWS
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
Boston Business Journal pulled together a list of the 25 biggest gainers in the state for 2017, and five of them are biopharma companies.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
The company is weeks away from completing its rolling NDA for Patisiran.
Alnylam and Sanofi Genzyme presented positive Phase III results of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy at a conference in France.
Alnylam and startup Vir Biotech inked a deal worth up to $1B for the development and marketing of RNAi therapies aimed at treating infectious diseases including HBV.
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
JOBS
IN THE PRESS